UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of September 2026
Commission File Number: 001-41773
Adlai Nortye Group Ltd.
77 Robinson Road
#20-01, Robinson 77
Singapore 068896
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
CONTENT
On September 8, 2026, Adlai Nortye Group Ltd. (previously known as Adlai Nortye Ltd.) (“Adlai Nortye” or the “Company”) issued a press release entitled “Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC”, a copy of the press release is attached to this Form 6-K as Exhibit 99.1.
Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release: Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-PAS(ON) Inhibitor-Based ADC |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Adlai Nortye Group Ltd. | ||
| By: | /s/ Yang Lu | |
| Name: | Yang Lu | |
| Title: | Chief Executive Officer and Chairman of Board of Directors | |
Date: September 8, 2026
2